Claim OwnershipMedEdTalks - Oncology
Subscribed: 14Played: 45
Subscribe
© 2019
Description
MedEdTalks Oncology is an accredited educational podcast for providers to learn more about treating patients with Oncology diseases/disorders. Discover all content and topics by visiting mededtalks.com.
14 Episodes
Reverse
Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with or without a checkpoint inhibitor.
Within this podcast, Mechanisms of Oncolytic Viral Therapy, Dr. Howard Kaufman and Professor Kevin Harrington review the rationale for the use of oncolytic viral therapies as monotherapy or in combination with checkpoint inhibitors for patients with advanced melanoma.
Within this podcast, Overview of Oncolytic Viral Therapy – Focus on Melanoma, Dr. Howard Kaufman and Dr. Dmitriy Zamarin evaluate the latest advances regarding the use of oncolytic viral therapy for cancer management, particularly in the context of advanced melanoma.
Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. Theses rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in the management of newly diagnosed PTCL. To earn CME credit, follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-updates-in-newly-diagnosed-ptcl Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_updates-in-newlydiagnosed-ptcl.pdf
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast expert clinicians will discuss antibody-drug conjugates in PTCL. To earn CME Credit, please follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-antibody-drug-conjugates-in-ptcl Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_antibodydrug-conjugates-in-ptcl.pdf
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss options for managing relapsed/refractory PTCL. To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-options-for-relapsed-refractory-ptcl
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in diagnosis of PTCL and the role of CD30. To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-updates-in-diagnosis-of-ptcl-and-the-role-of-cd30
Comments
Download from Google Play
Download from App Store
United States